What They Do
Recursion Pharmaceuticals uses artificial intelligence to accelerate drug discovery, combining massive biological datasets with machine learning to identify and develop new medicines. The company partners with major pharmaceutical companies like Sanofi and also develops its own clinical programs, generating revenue through partnership milestones, upfront payments, and potential future royalties. Their AI platform aims to make drug development faster, cheaper, and more predictable than traditional methods.
Investment Thesis
**Platform efficiency breakthrough**: Synthesizing 90% fewer compounds (300 vs 2,500 industry standard) and achieving 2x faster development timelines (17 vs 42 months), demonstrating clear competitive advantages**Strong partnership validation**: Over $500M in cumulative partner inflows with $134M from Sanofi alone, plus multiple programs each worth $300M+ in potential milestones and double-digit royalties**First clinical proof-of-concept achieved**: REC-4881 showing 43% median polyp reduction with 75% patient response rate, validating the AI-driven approach with tangible resultsKey Risks
**Negative gross margins of -62%**: Company is still burning significant cash with operating expenses of ~$390M annually and runway only to early 2028**Volatile earnings performance**: Recent quarters show inconsistent revenue beats ranging from -78.9% to +86.4%, indicating unpredictable milestone timingGrowth Story
Revenue is expected to decline from $95M (FTM) to $85M in 2026 before rebounding to $142M in 2027, reflecting the lumpy nature of milestone-driven biotech revenues. Growth is driven by advancing multiple clinical programs through key inflection points and hitting partnership milestones, with management expecting additional milestone achievements over the next 18 months across their diversified portfolio of 5+ programs.
Profitability Profile
The company is pre-profitability with significantly negative gross margins, but has demonstrated strong cost discipline by reducing operating expenses 35% year-over-year. Management projects losses narrowing from -$0.95 EPS in 2026 to -$0.85 in 2027, with a focus on "outcomes-based budgeting" to maximize value creation per dollar spent. Path to profitability depends on partnership milestone achievements and eventual royalty streams from successful drug approvals.
Competitive Position
Recursion operates in the emerging AI-powered drug discovery space, competing with traditional pharmaceutical R&D methods and other tech-bio companies. Their key differentiation lies in their integrated platform combining wet lab automation, massive biological datasets, and proprietary AI models, with strategic partnerships including technical collaborations with NVIDIA and Google Cloud. The platform's demonstrated efficiency metrics suggest a potentially sustainable competitive moat if clinical success continues.
Recent Momentum
The most recent quarter delivered a massive 86.4% revenue beat and $0.09 EPS beat, driven by achieving their first positive clinical proof-of-concept with REC-4881 and hitting the fifth milestone with Sanofi. This represents a strong turnaround from the prior quarter's -78.9% revenue miss, with management expressing increased confidence about upcoming clinical catalysts and FDA engagement planned for 2026.
What Wall Street Thinks
Analysts are cautiously optimistic following the strong clinical proof-of-concept but remain focused on the sustainability of cost reductions and the timing of future milestones. There's particular interest in the REC-4881 regulatory pathway and questions about whether the recent operational efficiency gains are sustainable. The volatile earnings pattern has created uncertainty about revenue predictability despite the partnership validation.
The Bottom Line
Recursion has achieved a critical inflection point with its first clinical proof-of-concept, validating its AI-driven drug discovery platform, but investors need to weigh the compelling technology story against significant cash burn and the inherent risks of early-stage biotech execution.
